Immunwork

@immunwork.com

Immunwork, Inc. located in Taipei, Taiwan was founded in October 2014.After a corporate reorganization in November 2019, Immunwork is now a wholly owned subsidiary of T-E Pharma Holding, incorporated in Cayman Island. Immunwork focuses on the research and development of a class of new drugs, which are created based on our proprietary “T-E pharmaceuticals” technology platform. The first group of new drugs is for treating several types of cancer, diabetes, obesity, fatty liver diseases, and pathological blood clots.

immunwork.com

Immunwork's Company Logos

Immunwork's Brand Colors

Hex Code

Color name

RGB

HSL

CMYK

#54FF2D

Harlequin

84, 255, 45

109, 100, 59

67, 0, 82, 0

#FFFFFF

White

255, 255, 255

0, 0, 100

0, 0, 0, 0

#334155

Pickled Bluewood

51, 65, 85

215, 25, 27

40, 24, 0, 67

About Immunwork

Immunwork, Inc., based in Taipei, Taiwan, is a pioneering brand that specializes in the research and development of innovative drugs. Established in October 2014, Immunwork became a wholly owned subsidiary of T-E Pharma Holding in November 2019. The brand is dedicated to creating a new class of drugs using their revolutionary T-ETM pharmaceuticals technology platform.

Immunwork focuses on developing drugs that effectively treat various conditions, including cancer, diabetes, obesity, fatty liver diseases, and pathological blood clots. Their products, such as TE-1146, TE-1132, TE-8105, TE-8035, TE-8214, and TE-6168, are designed to carry both targeting (T) and effector (E) functions, thereby increasing efficacy and safety. With a vision rooted in self-growth and social responsibility, Immunwork places great importance on teamwork and patience.

They strive to enhance the efficacy and safety of drug treatments while providing innovative solutions to meet the evolving needs of patients. For more information and inquiries, please contact Immunwork via email at bd@immunwork. com or service@immunwork.

com, or reach them by phone at +886-2-2651-2268